Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a r ...
Moderna receives MHRA marketing authorization for RSV vaccine
Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of ...
UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older
Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna to Present at Upcoming Conferences in March 2025
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
devdiscourse1d
A Global Health Update: From Flu Discussions to Weight-Loss Drug Wars
U.S. involvement in WHO flu meetings, the UK's approval of Moderna's RSV vaccine, efforts against a measles outbreak in Texas ...